PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals
February 17, 2021
PharmaTher Announces Sale of Psilocybin Program
February 4, 2021
PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson's Disease
February 1, 2021
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Delivery Ketamine
